Coramitug治疗转甲状腺素蛋白淀粉样变心肌病的2期随机对照试验
这项2期双盲安慰剂对照试验将104例转甲状腺素蛋白淀粉样变心肌病患者随机分配至coramitug 10 mg/kg、60 mg/kg或安慰剂组,每4周输注一次共52周。主要终点为6分钟步行试验和NT-proBNP变化;60 mg/kg组NT-proBNP较安慰剂显著降低48%(95%CI -65%至-22%,P=0.0017),但6分钟步行试验无统计学差异,药物耐受性良好。
要点
- coramitug 60 mg/kg每4周输注可显著降低NT-proBNP达48%。
- 6分钟步行试验在两种剂量下均未显示统计学显著改善。
- coramitug 60 mg/kg耐受性良好并改善功能性超声心动图参数。
核心结论
- coramitug 60 mg/kg在52周内显著降低NT-proBNP,但6分钟步行试验无统计学显著变化。
- coramitug耐受性良好,60 mg/kg与功能性超声心动图参数改善相关。
研究设计与样本
- 2期随机、双盲、多中心、安慰剂对照试验,纳入104例转甲状腺素蛋白淀粉样变心肌病患者。
- 随机按1:1:1分配至coramitug 10 mg/kg、60 mg/kg或安慰剂,每4周输注一次,持续52周。
- 主要终点为基线至第52周6分钟步行试验和NT-proBNP水平的变化。
- 安全性评估长达64周,包括治疗中出现的不良事件、全因死亡和心血管事件数。
主要发现
- 60 mg/kg coramitug组NT-proBNP较安慰剂降低48%(95%CI -65%至-22%;P=0.0017)。
- 两种剂量coramitug的6分钟步行试验变化与安慰剂相比均无统计学差异。
- 60 mg/kg coramitug与功能性超声心动图参数改善相关,且耐受性良好。
- 基线中位NT-proBNP为1985 pg/mL(四分位距1224至3406)。
- 90%参与者接受疾病修饰治疗,其中84%使用tafamidis,7例(6.7%)使用TTR沉默剂。
关键数值与推荐
- 52周时60 mg/kg coramitug组NT-proBNP较基线降低48%(95%CI -65%至-22%;P=0.0017)。
临床怎么用
- coramitug 60 mg/kg每4周输注可作为降低NT-proBNP的潜在治疗选择,但6分钟步行试验未获益。
- 治疗决策需综合考虑NT-proBNP下降与功能终点未改善之间的差异。
局限性
- 样本量小(共104例),随访期52周。
- 多数参与者为男性(93%)、NYHA II级(84%)且接受tafamidis治疗(84%)。
- 6分钟步行试验未显示统计学显著改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive disease caused by the deposition of transthyretin (TTR) as amyloid in the myocardium. Current therapies may slow disease progression but do not clear existing deposits. Coramitug is a humanized monoclonal antibody that targets misfolded transthyretin, designed to promote clearance of transthyretin amyloid through antibody-mediated phagocytosis. METHODS: This phase 2, double-blind, placebo-controlled trial randomized participants with transthyretin amyloidosis with cardiomyopathy to receive infusions every 4 weeks of either coramitug at 2 dosages (10 mg/kg or 60 mg/kg) or placebo in a 1:1:1 ratio for 52 weeks. The primary end points were the change from baseline to week 52 in the 6-minute walk test and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels. Safety was assessed for up to 64 weeks by assessing treatment-emergent adverse events, all-cause mortality, and number of cardiovascular events (comprising hospitalization caused by cardiovascular events or urgent heart failure visits). RESULTS: In total, 104 participants (median age, 77 years; 93% men; 84% New York Heart Association class II; 13% with variant transthyretin amyloidosis with cardiomyopathy) were randomized and dosed: 34 to 10 mg/kg of coramitug, 35 to 60 mg/kg of coramitug, and 35 to placebo. Median NT-proBNP was 1985 pg/mL (interquartile range, 1224, 3406). In total, 90% of participants were receiving disease-modifying therapy; 84% were treated with tafamidis and 7 (6.7%) with transthyretin silencers (patisiran, n=4; vutrisiran, n=3). From baseline to week 52, 60 mg/kg of coramitug significantly reduced NT-proBNP levels compared with placebo (-48% [95% CI, -65% to -22%]; P=0.0017). The change in 6-minute walk test from baseline to week 52 was not statistically different from placebo with either dose. Coramitug (60 mg/kg) was associated with improved functional echocardiographic parameters and was well tolerated. CONCLUSIONS: This phase 2 trial showed that coramitug, an antibody targeting misfolded transthyretin in transthyretin amyloidosis with cardiomyopathy, was well tolerated and, at a dose of 60 mg/kg, resulted in a statistically significant reduction in NT-proBNP, a validated marker of disease progression, with no statistically significant effect on 6-minute walk test within 52 weeks. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05442047.
引用
- Fontana M, García-Pavía P, Grogan M, et al. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Circulation. 2025. PMID: 41212997. doi:10.1161/CIRCULATIONAHA.125.077304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。